不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
复发/难治性弥漫大 B 细胞淋巴瘤治疗中 ADC 的基础知识
英文原题：ABCs of ADCs in management of relapsed/refractory diffuse large B-cell lymphoma.
查看英文原题
ABCs of ADCs in management of relapsed/refractory diffuse large B-cell lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
过去5年，美国食品药品监督管理局已批准用于复发／难治性（R/R）弥漫性大B细胞淋巴瘤（DLBCL）患者的疗法包括3种嵌合抗原受体（CAR）T细胞疗法、2种抗体药物偶联物（ADC）、1种靶向CD19的单克隆抗体和1种核输出蛋白1抑制剂。非细胞疗法的加速批准依据是临床试验总缓解率；这些试验在入组患者的年龄、体能状态、既往治疗线数，以及是否纳入原发难治性DLBCL、转化型淋巴瘤或MYC与BCL2和／或BCL6重排的高级别B细胞淋巴瘤等方面存在多项差异。获批用于DLBCL的ADC在靶抗原、抗体结构、连接子和细胞毒药物方面有所不同，因此安全性及疗效特征也各异。本文全面回顾近期获批及正在研发的R/R DLBCL治疗策略，重点介绍ADC。
展开英文摘要原文
In the past 5 years, 3 chimeric antigen receptor (CAR) T-cell therapies, 2 antibody-drug conjugates (ADCs), 1 CD19-directed monoclonal antibody, and 1 exportin-1 inhibitor have been approved by the Food and Drug Administration for patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
The noncellular therapies received accelerated approval based on the overall response rate in clinical trials that differ in multiple aspects of the patient populations enrolled, including age, performance status, prior lines of therapy, and inclusion of patients with primary refractory DLBCL, transformed lymphoma, or high-grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6. ADCs approved for DLBCL differ in target antigen, antibody structure, linker, and cytotoxin, which results in a different safety and efficacy profile.
Here, we comprehensively review the current knowledge of recently approved and emerging strategies for the management of R/R DLBCL with a focus on ADCs.
论文信息
- 作者
- Alderuccio JP、Sharman JP
- 单位
- Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA. Electronic address: jalderuccio@med.miami.edu.United States
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Blood reviews2022 Nov
- 原文标识
- PubMed 35489963 · DOI 10.1016/j.blre.2022.100967